Your fact-checks will appear here
Development of drugs for Alzheimer's disease, including targets such as amyloid, tau, and neurotransmitter receptors
Low‑dose methylene blue (and its reduced proprietary forms LMTM/HMTM) remains under active clinical investigation for Alzheimer’s disease (AD) in a small set of randomized trials that focus on short‑t...
The clinical literature contains a small number of trials that have administered Bacopa monnieri to people with Alzheimer’s disease, but none constitute incontrovertible, high‑quality evidence: a 2022...
There is no reliable, conclusive evidence that Neurocept capsules “repair” dementia-damaged brain cells; marketing materials portray broad cognitive benefits while independent reviews and regulators w...
Reporting assembled for this brief finds no detailed, peer‑reviewed randomized controlled trial (RCT) record for a drug explicitly named “Neurocept” in the provided sources; the only source that menti...
There are no data in the provided reporting that describe the composition, pharmacology, or clinical testing of a product called “Neuro Defender,” so a definitive, evidence-based statement about direc...